Double-blind and open studies of lithium prophylaxis in affective disorders
There is now abundant evidence that the morbidity of recurrent affective disorders continues to be high even when treated by the best conventional methods. Continuous lithium treatment has now been shown to considerably reduce the morbidity of both unipolar recurrent depressive patients and both the manic and depressive phase of the bipolar patients.
Available from: Mirko Manchia
- "In BD, efforts thus far to develop a stringent definition of treatment response, especially in long-term therapies, have applied analytical tools such as the Affective Morbidity Index (AMI)   and the illness severity index . Briefly, these approaches take into consideration the severity and the duration of episodes before and after the introduction of the mood stabilizing therapy, allowing quantification of the degree of improvement under a specific treatment. "
[Show abstract] [Hide abstract]
ABSTRACT: Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by manic and depressive episodes. Among the most effective treatments, mood stabilizers represent the keystone in acute mania, depression, and maintenance treatment of BD. However, treatment response is a highly heterogeneous trait, thus emphasizing the need for a structured informational framework of phenotypic and genetic predictors. In this paper, we present the current state of pharmacogenomic research on long-term treatment in BD, specifically focusing on mood stabilizers. While the results provided so far support the key role of genetic factors in modulating the response phenotype, strong evidence for genetic predictors is still lacking. In order to facilitate implementation of pharmacogenomics into clinical settings (i.e., the creation of personalized therapy), further research efforts are needed.
Available from: Charles L Bowden
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.